Artiva Shuts NK Cell Program AlloNK After Conditioning Chemo Kills Patient in Outpatient Trial
· techtimes.com · popularity 16/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at techtimes.com →
Summary
Artiva Biotherapeutics permanently discontinues AlloNK, its lead NK cell therapy, after a patient dies of fludarabine-linked brain damage in an outpatient autoimmune trial that also failed long-term durability testing. Artiva is cutting 94% of its workforce and engaging Leerink Partners to find a buyer, retaining $319 million in preliminary cash.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 19.